- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.02. | UK government launches 'landmark' AI breast cancer screening trial | ||
| 04.02. | World Cancer Day - CoppaFeel! and NHS NELCA urge young people to 'Check In' | ||
| 04.02. | Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer | ||
| 04.02. | BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer | ||
| 04.02. | Celebrating collective achievement - the power of collaboration | ||
| 03.02. | AstraZeneca's Imfinzi recommended by CHMP to treat small cell lung cancer | ||
| 03.02. | J&J's subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer | ||
| 03.02. | MHRA approves CSL's Andembry to treat angioedema attacks in HAE patients | ||
| 03.02. | FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors | ||
| 03.02. | Optimising business partnerships for success and sustainability | ||
| 31.01. | Amgen's Blincyto granted EC approval for new acute lymphoblastic leukaemia indication | ||
| 31.01. | NICE approves Vertex's Casgevy one-time gene therapy for sickle cell disease | ||
| 31.01. | ICR researchers uncover new method for predicting bowel cancer risk in IBD patients | ||
| 31.01. | Keto, CAR-T and creativity: insights from ASH 2024 | ||
| 30.01. | UK access pathway launched to get new medicines to patients in 'shortest time possible' | ||
| 30.01. | Sanofi's Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma | ||
| 30.01. | Roche shares overall survival results for Itovebi in advanced breast cancer | ||
| 30.01. | The AI tipping point in pharma marketing: balancing technology and trust | ||
| 29.01. | Biogen's higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA | ||
| 29.01. | Novo Nordisk's Ozempic granted FDA approval in chronic kidney disease | ||
| 29.01. | Bayer UK launches digital educational hub to improve menopause support | ||
| 29.01. | Back to work | ||
| 28.01. | AstraZeneca/Daiichi Sankyo's Enhertu granted FDA approval in breast cancer | ||
| 28.01. | Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy | ||
| 28.01. | BMS presents promising data for immunotherapy combination in phase 3 colorectal cancer trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
